Features of immunophenotypic finding B-cell lymphoproliferative diseases by flow cytometry

Abstract

Aim. To assess the information content of conventional and additional immunophenotypic markers (CD200, CD305) in the differential diagnosis B-cell lymphoproliferative diseases by flow cytometry.

Methods. An immunophenotypic study using 4-color flow cytometry was performed in 204 patients with diffe­rent variants of B-cell non-Hodgkin's lymphomas. The study material included peripheral blood and bone marrow. The expression of CD45, CD19, CD20, CD22, CD79b, CD79a, CD5, CD10, CD23, FMC7, CD43, CD38, CD11c, CD103, CD25, CD 200, CD 305, light chains of immunoglobulins (kappa/lambda) using monoclonal antibodies (Becton Dickinson, USA) was evaluated. The intensity of antigen expression was assessed using mean fluorescence intensity (y. e.).

Results. Conventional FMC7-positive expression revealed only half patients with different variants of leu­kemization of non-Hodgkin's lymphomas, whereas atypical positive expression of CD23 was observed in patients with marginal spleen lymphoma and follicular lymphoma in 27.3 and 28.6% of cases, respectively. In mantle cell lymphoma, expression of CD200 in B-cell was detected in a significantly smaller number of observations, accompanied by a significant decrease in the average intensity of CD200 fluorescence compared to B-cell chronic lymphocytic leukemia (B-CLL) cells. The mean fluorescence intensity (MFI) of CD305 in hairy cell leukemia is significantly higher than in splenic marginal zone lymphoma (SMZL) with “villous” lymphocytes.

Conclusion. Different levels of the information content of some conventional markers were revealed in differential immunophenotypic diagnosis of B-cell lymphoproliferative diseases by flow cytometry; the use of additio­nal markers CD200 and CD305 was highly informative in differential diagnostics between different variants of B-cell lymphoproliferative diseases with similar immunophenotypic and morphological characteristics of lymphoid elements.

Keywords

B-cell lymphoproliferative diseases / flow cytometry / СD200 / СD305 markers

References

[1] WHO Classification of Tumours of Haematopoe­tic and Lymphoid Tissues. Ed. S.H. Swerdlow, E. Campo, N.L. Harris et.al. Lyon. 2017; 585 р.

[2] Lugovskaya S.A., Kisilichina D.G., Pochtar M.E. et al. New markers (CD160, CD200, and LAIR-1) in diagnosis of B-cell lymphoproliferative disorders. Klinicheskaya onkogematologiya. Fundamental'nye issledovaniya i klinicheskaya praktika. 2013; 6 (1): 45–53. (In Russ.)

[3] Луговская С.А., Кисиличина Д.Г., Почтарь М.Е. и др. Новые маркёры (CD160, CD200, LAIR-1) в диагностике В-клеточных лимфопролиферативных заболеваний. Клин. онкогематол. Фудаментал. исслед. и клин. практика. 2013; 6 (1): 45–53.

[4] Palumbo G.A., Parrinello N., Fargione G. et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk. Res. 2009; 33 (9): 1212–1216. DOI: 10.1016/j.leukres.2009.01.017.

[5] Brunetti L., Di Noto R., Abate G. et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br. J. Haematol. 2009; 145 (5): 665–667. DOI: 10.1111/j.1365-2141.2009.07644.x.

[6] Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin. Diagn. Pathol. 2011; 28 (3): 245–255. DOI: 10.1053/j.semdp.2011.02.010.

[7] Moreaux J., Hose D., Reme T., Jourdan E. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006; 108 (13): 4194–4197. DOI: 101182/blood-2006-06-029355.

[8] Olteanu H., Harrington A.M., Parameswaran H., Kroft S.H. CD200 expression in plasma cell myeloma. Br. J. Haematol. 2011; 153: 408–411. DOI: 10.1111/j.1365-2141.­2010.08555.x.

[9] Desoukey N.A., Afify R.A., Amine D.G., Mohammed R.F. CD200 expression in B-cell chronic lymphoproliferative disorders. J. Investig. Med. 2012; 60: 56–61. DOI: 10.2310/JIM.0b013e31823908f9.

[10] Brondijk C., de Ruiter T., Ballering J. et al. Crystal structure and collagenbinding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen bin­ding by platelet receptor GPVI. Blood. 2010; 115 (7): 1364–1373. DOI: 10.1182/blood-2009-10-246322.

[11] Meyaard L. The inhibitory collagen receptor ­LAIR-1 (CD305). J. Leuk. Biol. 2008; 83: 799–803. DOI: 10.1189/Jeb.0907609.

[12] Alfarano A., Indraccolo S., Circosta P. et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999; 93 (7): 2327–2335. PMID: 10090943.

[13] Krober A., Seiler T., Benner A. et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002 (100): 1410–1416. PMID: 12149225.

[14] Quijano S., López A., Rasillo A. et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferativerate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry. Part B. Clin. Cytom. 2008; 74B (3): 139–149. DOI: 10.1002/cyto.b.20390.

[15] Muzio M., Scielzo C., Bertilaccio M.T. et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol. 2009; 144 (4): 507–516. DOI: 10.1111/j.1365-2141.2008.07475.x.

[16] Chuksina Y.Y., Yazdovskiy V.V., Shevelev S.V. et al. Prognostic significance of immunophenotypic markers in the evaluation of minimal residual disease in patients with chronic lymphocytic leukemia after immunochemotherapy. Rossiyskiy immunologicheskiy zhurnal. 2015; 9 (3-1): 236–238. (In Russ.)

[17] Чуксина Ю.Ю., Яздовский В.В., Шевелёв С.В. и др. Прогностическая значимость иммунофенотипических маркёров при оценке минимальной остаточной болезни у больных хроническим лимфолейкозом после проведения иммунохимиотерапии. Рос. иммунол. ж. 2015; 9 (3-1): 236–238.

[18] Katzenberger T., Kalla J., Leich E. et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009; 113 (5): 1053–1061. DOI: 10.1182/blood-2008-07-168682.

RIGHTS & PERMISSIONS

Chuksina J.J., Kataeva E.V., Mitina T.A.